Compare Global X Data Center & Digital Infra ETF (DTCR) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Data Center & Digital Infra ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Global X Data Center & Digital Infra ETF trades at $27.9 (market cap $2.04B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 12.4× Global X Data Center & Digital Infra ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Global X Data Center & Digital Infra ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Data Center & Digital Infra ETF for 15 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| DTCR | RPRX | |
|---|---|---|
Market Cap | $2.04B | $25.27B |
Volume | 899,532 | 3,671,183 |
Sector | Sector/Thematic | Health |
52-Week High | $32.46 | $63.96 |
52-Week Low | $19.73 | $35.44 |
Typical Hold Time | 15 Days | 1 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Data Center & Digital Infra ETF
Global X Data Center & Digital Infrastructure ETF seeks exposure to companies involved in data centers and digital infrastructure. Its holdings span areas such as digital infrastructure, networking, and related real estate.
Read more on DTCR →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
